Physician profile
David C Tabor
NPI 1720097231
$4,354.28
in general payments reported to CMS, 2019-2025
34 companies · $30.33 in 2025
The $30.33 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $353 · 2021: $446 · 2022: $551 · 2023: $701 · 2024: $1,426 · 2025: $30.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,025 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,024.95 |
| Education | $133.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $784.66 | 2019-2024 | Xifaxan, Trulance |
| Abbvie INC. | $711.94 | 2019-2024 | Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $650.00 | 2019-2025 | Entyvio, Glassia, Eohilia |
| Janssen Biotech, INC. | $433.00 | 2019-2024 | Stelara, Simponi Aria, Simponi |
| Celgene Corporation | $231.07 | 2022-2024 | Zeposia |
| Allergan, INC. | $173.63 | 2019 | |
| Gilead Sciences, INC. | $135.50 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $132.06 | 2023-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $93.70 | 2019-2024 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $89.07 | 2024 | Iqirvo, Bylvay |
| Pfizer INC. | $84.52 | 2019-2022 | |
| Genzyme Corporation | $66.45 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.62 | 2022-2024 | Cyltezo, Ofev |
| Capsovision, INC. | $59.08 | 2024-2025 | Capsocam Plus |
| Merck Sharp & Dohme LLC | $56.33 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $54.47 | 2023-2024 | Hadlima, Renflexis |
| Celltrion USA INC. | $49.93 | 2024 | Zymfentra, Vegzelma |
| Nestle Healthcare Nutrition INC. | $46.83 | 2021 | |
| Lilly USA, LLC | $46.49 | 2024 | Omvoh |
| Ardelyx, INC. | $44.31 | 2023-2024 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $43.62 | 2019-2020 | |
| Shionogi INC | $40.26 | 2019 | |
| Braintree Laboratories, INC. | $40.03 | 2020-2021 | |
| Ucb, INC. | $39.52 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $29.51 | 2024 | Idacio |
| Madrigal Pharmaceuticals | $22.00 | 2024 | Resmetirom |
| Aimmune Therapeutics, INC. | $20.78 | 2024 | |
| Alexion Pharmaceuticals, INC. | $19.70 | 2019 | |
| Redhill Biopharma INC. | $18.18 | 2020 | |
| Endo Pharmaceuticals INC. | $17.96 | 2020 | |
| Ferring Pharmaceuticals INC. | $14.52 | 2020 | |
| Sandoz INC. | $14.28 | 2023 | Hyrimoz |
| Daiichi Sankyo INC. | $13.95 | 2019 | |
| Qol Medical, LLC | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tabor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.